Navigation Links
New vaccine may give long-term defense against deadly bird flu and its variant forms
Date:4/17/2008

WEST LAFAYETTE, Ind. - A new vaccine under development may provide protection against highly pathogenic bird flu and its evolving forms, according to researchers at Purdue University and the Centers for Disease Control and Prevention who discovered the new preventative drug and have tested it in mice.

Unlike traditional influenza vaccines, the new vaccine could be produced quickly and stored for long periods in preparation for a pandemic of dangerous disease-causing avian influenza - H5N1 - and its variants, said Suresh Mittal, a Purdue virologist. In an earlier study with mice, he and his colleagues found that the vaccine protected against H5N1 for a year or longer. Because the studies have only been done in mice, it's not yet known whether the same results will be obtained in humans.

"We want to have a vaccine that can be stored in advance and have the potential to provide protection for a period of time until we can change the vaccine to match the latest form of avian influenza," Mittal said. "The combination of flu genes that we've used to produce the vaccine, I think, will provide that capability."

The importance of having a long-lasting, broadly protective vaccine is that it would give some cross-protection against new viruses with pandemic potential caused by mutations in currently circulating H5N1 viruses. This would give scientists time to develop a better vaccine that would match the latest form of the bird flu.

Mittal and his colleagues, including Suryaprakash Sambhara, the CDC principal investigator on the project, report their findings on the vaccine in the April 15 issue of The Journal of Infectious Diseases. In the December issue of Clinical Pharmacology and Therapeutics, Mittal, Sambhara and their collaborators published their findings of the long-lasting capabilities of the vaccine.

"In humans we want a vaccine to be fully effective for at least a year," said Mittal, a professor of comparative
'/>"/>

Contact: Susan A. Steeves
ssteeves@purdue.edu
765-496-7481
Purdue University
Source:Eurekalert  

Page: 1 2 3 4

Related biology news :

1. Possible hepatitis C vaccine
2. Study by Pittsburgh researchers identifies possible vaccine target for chlamydia
3. New nanoparticle vaccine is more effective but less expensive
4. Flu vaccine in painless skin patches under development at Emory, Georgia Tech with NIH grants
5. Influenza vaccine causes weaker immune response for children of rural Gabon than in semi-urban areas
6. An Alzheimers vaccine?
7. Penn researchers find monkeys able to fend off AIDS-like symptoms with enhanced HIV vaccine
8. CWRU School of Medicine has evidence vaccine against malaria will reduce disease
9. HIV isolate from Kenya provides clues for vaccine design
10. Iowa State researchers look for smaller, cheaper, 1-dose vaccines
11. Vaccine for Ebola virus
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New vaccine may give long-term defense against deadly bird flu and its variant forms
(Date:8/20/2014)... grows to about 4,000 members, it triggers an important ... a special type of comb used for rearing male ... Department of Neurobiology and Behaviour at Cornell University, led ... of honeybee colonies. The results are published in Springer,s ... , Reproduction isn,t always a honeybee colony,s top ...
(Date:8/20/2014)... 20, 2014  The second annual Biometrics UnPlugged ... Tampa, Florida on September 15, ... Rahman, Director, Technology and Strategy at Samsung, and Philippe ... theme of this year,s event is Mobility at ... "Biometrics UnPlugged: Mobility at the Crossroads of ...
(Date:8/19/2014)... is available in German . ... intermittent energy sources. If a large amount of electricity is ... excess energy will have to be stored during productive periods ... storage capacities are far from adequate for the purpose. Science ... important focus lies on battery systems that used to be ...
Breaking Biology News(10 mins):Worker bees 'know' when to invest in their reproductive future 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3
... A*STAR scientists from the Institute of Molecular and Cell Biology ... 100 years, by constructing stable haploid strains of ... This discovery, jointly made by two teams of scientists led ... Berman of the University of Minnesota, will enable scientists to ...
... Chronicle of Higher Education , the National Institutes ... in the review of grant applications. (Found at: ... professor of biomedical engineering at the Virginia ... Engineering and Sciences , and seven of his ...
... the journal Science , today announces the 53 ... Technology Visualization Challenge, a highly competitive contest jointly sponsored ... magazine is published by the American Association for the ... than 200 entries from 18 countries, including entries from ...
Cached Biology News:A*STAR scientists solve century-old mystery by finding stable haploid strains of Candida albicans 2Virginia Tech adjunct and colleagues refute a study on 'racial bias' report in NIH awards 2Virginia Tech adjunct and colleagues refute a study on 'racial bias' report in NIH awards 3Winners of 10th annual International Science & Technology Visualization Challenge announced 2Winners of 10th annual International Science & Technology Visualization Challenge announced 3
(Date:8/21/2014)... Wednesday of last week RENU 28, the world's first and ... for purchase in Australia and New Zealand, and the response ... is, if you think about the definition of aging, it's ... within your body. If you think about the definition of ... What RENU 28 does is it works with these tiny ...
(Date:8/20/2014)... Neurotrope, Inc. (OTCQB: NTRP) today announced ... provide an update on Company activities. Access information:Date:Tuesday, ... 505-4369 (U.S. and Canada) or (719) 325-2315 Conference ... under "Investor Relations"The teleconference replay will be available ... 2014 at (888) 203-1112 (U.S. and ...
(Date:8/20/2014)... 2014 Not long ago, it was ... be performed late in the development cycle – even ... regulatory trends suggest that, like many things GxP, expectations ... recent years, multiple drug sponsors have been required by ... questions during phase I/II. It’s not only clinical trial ...
(Date:8/19/2014)... 2014 One of the major ... an inadequate vascular supply. Nutrient and gas transport ... is critical for successful regeneration and integration into ... deficiencies in vascularization and promote angiogenesis in a ... scaffold design and architecture, and enhancing scaffolds with ...
Breaking Biology Technology:RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... Vivo Ventures, a venture,capital firm specializing in life ... firm as an Executive in Residence. With his,extensive business ... portfolio companies while enhancing the firm,s presence in,Asia. ... what he will be able to,bring to Vivo," said ...
... Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that ... U.K. Phase Ia/Ib combination,REOLYSIN(R)/radiation clinical trial for ... to be presented today at the AACR-NCI-EORTC,International ... in,San Francisco. The conference runs from October ...
... 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ... letter of approval from the U.K. Medicines ... Clinical Trial Application (CTA) to begin,a clinical ... with cyclophosphamide, a chemotherapeutic agent as well ...
Cached Biology Technology:Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence 2Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 2Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 3Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide 2Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide 3
Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
Request Info...
Cyan Standard is 7-hydroxy-4-trifluoromethylcoumarin...
Green Standard is fluorescein....
Biology Products: